The Center for Cancer & Blood Disorders

What The Center for Cancer & Blood Disorders does

The Center for Cancer & Blood Disorders (CCBD) is an independent, physician-owned community oncology practice founded in 1990 and headquartered in Fort Worth, Texas. It operates 22 clinic locations across the DFW metroplex — including Fort Worth, Dallas, Plano, Denton, McKinney, Arlington, Irving, and Southlake — and serves more than 25,000 cancer and blood disorder patients annually through a multidisciplinary team of 46+ board-certified physicians and advanced practitioners covering medical, surgical, and radiation oncology, hematology, and integrative medicine, with multilingual capability across 8 languages.

CCBD delivers a broad portfolio of clinical services spanning chemotherapy, immunotherapy, targeted therapy, hormone therapy, biologic and bispecific T-cell engager (BiTE) therapy, radiopharmaceutical therapy, infusion and on-site pharmacy, hematology (including benign hematology), surgical oncology and tumor resection, interventional radiology, low-dose radiation therapy for benign conditions, imaging, pathology, and a clinical trials and research program led by Dr. Ray Page covering 200+ trials and 60+ experimental drugs over 27+ years. In February 2026, CCBD launched a community-based CAR-T (Chimeric Antigen Receptor T-Cell) therapy program — enabled by Texas House Bill 3057 — becoming one of the first independent Texas oncology practices to deliver this advanced cellular therapy outside a hospital or academic center, with care coordinated through a partnership with Medical City Fort Worth. Technology infrastructure is conventional healthcare IT: a NavigatingCare-based electronic medical record and patient portal, plus a MyPay billing system. There are no proprietary AI/ML models, patents, or software products disclosed in the source material.

CCBD generates revenue primarily through fee-for-service medical, surgical, and radiation oncology billed to commercial insurers, Medicare, and Medicaid, supplemented by infusion and on-site pharmacy services and clinical trial participation revenue. Go-to-market is sales-led and geographically anchored: physician referrals, self-referrals, hospital partnerships, and community outreach drive patient acquisition across the DFW footprint. The practice is a partner practice of OneOncology, a national network of independent community oncology practices, and in October 2025 entered a partnership with Adjutant Behavioral Health to integrate psychological and medication management support into oncology care. Revenue figures are not publicly disclosed.

Name

The Center for Cancer & Blood Disorders

Legal name

The Center for Cancer and Blood Disorders

Website

https://thecentertx.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

251–500 employees

Short description

The Center for Cancer & Blood Disorders is an independent community oncology practice serving 25,000+ cancer and blood disorder patients annually across 22 DFW metroplex locations through medical, surgical, and radiation oncology, hematology, CAR-T therapy, infusion pharmacy, and clinical trials.

Ownership category

akta.pro rank

Product category

Oncology and Hematology Services

NAICS

Offices of Physicians (62111), Ambulatory Health Care Services (621)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro industry

PRIMARYHLAFABAI

Ambulatory Oncology Centers (Outpatient Chemo/Radiation)

Healthcare & Life Sciences/Healthcare Providers & Systems/Ambulatory & Outpatient Care Centers

SECONDARYHLAAABAJ

Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring)

Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

• Oncology services
• Cancer treatment
• Hematology care
• Radiation oncology
• Infusion therapy

Headquarters

HQ city

Fort Worth

HQ country

United States

HQ region

North America

Offices22 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Medical Services Revenue: Revenue generated from providing medical oncology, hematology, radiation oncology, surgical oncology, and related cancer treatment services. Billed through insurance plans, Medicare, Medicaid, and other third-party payers.
2. Infusion and Pharmacy Services: On-site pharmacy and infusion therapy services generating revenue through medication administration and related patient care services.
3. Clinical Trial Research: Research program providing patients access to clinical trials, potentially including sponsor payments for trial participation.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

The Center for Cancer & Blood Disorders is a private community oncology practice that delivers multi-specialty cancer care — including medical oncology, surgical oncology, radiation oncology, hematology, immunotherapy, and CAR-T cell therapy — to patients across the DFW metroplex through 22 clinic locations. Its offering combines treatment services (chemotherapy, targeted therapy, infusion therapy, on-site oncology pharmacy) with supportive care (palliative care, nutritional and genetic counseling, social work) and a long-running Clinical Trials & Research program. Patients access the practice directly, through physician referrals, or via hospital partnerships for advanced therapies delivered jointly with local hospitals.

Product overview

The Center for Cancer & Blood Disorders (CCBD) is a community oncology practice offering comprehensive cancer care services across the DFW metroplex through a multi-location network. The practice provides a broad portfolio of medical, surgical, and radiation oncology services including Medical Oncology, Surgical Oncology, Radiation Oncology, Hematology, Immunotherapy, and CAR-T Therapy. CCBD operates as an integrated care platform offering both core treatment services (Chemotherapy, Targeted Therapy, Hormone Therapy, Biologic Therapy) alongside supportive care services (Nutritional Counseling, Palliative Care, Social Work, Patient Support Services, Genetic Counseling). The practice also maintains Clinical Trials & Research programs led by Dr. Ray Page with over 200 clinical trials available. With 22 locations across North Texas, CCBD serves more than 25,000 patients annually through a team of 46+ oncology physicians and specialists.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical Oncology Systemic cancer treatment service using medications that work throughout the body, including chemotherapy, immunotherapy, targeted therapy, and hormone therapy, for patients with solid tumors, blood cancers, and related malignancies.
• Surgical Oncology Surgical oncology services that use surgery to diagnose, stage, treat, or help prevent cancer, including tumor resection/excision, lymph node dissection, and supportive surgical procedures.
• Radiation Oncology Radiation oncology services delivering highly targeted, high-energy radiation to destroy cancer cells and shrink tumors, including low-dose radiation therapy for benign conditions.
• Hematology Specialty hematology service for blood cancers and benign hematology conditions including leukemia, lymphoma, and related disorders.
• Immunotherapy Cancer treatment service that harnesses the body's immune system to fight cancer cells, including BiTE (Bispecific T-Cell Engager) therapy and other immune-directed modalities.
• CAR-T Therapy Program Chimeric Antigen Receptor T-Cell therapy delivered in a community practice setting, modifying a patient's T-cells to target cancer cells; CCBD was one of the first independent Texas oncology practices to offer this outside a hospital or academic center and the first in Tarrant County to treat a patient with it.
• Infusion Therapy Infusion therapy service that delivers medication directly into the bloodstream via intravenous administration for cancer treatment.
• Oncology Pharmacy On-site pharmacy services providing medications and clinical pharmacy support for cancer patients receiving treatment.
• Clinical Trials & Research Clinical research program giving cancer patients access to innovative treatments being studied for safety and effectiveness, led by Dr. Ray Page and supported by 27+ years of experience running 200+ trials across 60+ experimental drugs.
• Palliative Care Supportive service focused on providing relief from the symptoms and stress of serious illness, improving quality of life for cancer patients and families.
• Genetic Counseling & Testing Genetic counseling and testing service evaluating hereditary cancer risk and providing counseling based on results for patients and families.
• Diagnostic Imaging and Interventional Radiology Diagnostic imaging and minimally invasive image-guided procedures used for cancer diagnosis, staging, and treatment.

Quantifiable outcome

• More than 25,000 patients served annually
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Adjuvant Behavioral HealthcoreStrategic or Co-development Partner · 1 October 2025Partnership to integrate behavioral health services into oncology care across North Texas. Effective October 1, 2025, the collaboration includes a referral agreement to provide psychological and medication management support to cancer patients. This partnership supports CCBD's whole-person care approach, addressing the emotional and psychological needs of patients throughout their cancer journey.
• Medical City Fort WorthcoreStrategic or Co-development PartnerLocal hospital partnership enabling coordinated CAR-T therapy delivery. The CAR-T care delivery model allows seamless monitoring and care coordination between CCBD's physician-based clinic and Medical City Fort Worth, ensuring patient safety and improving treatment outcomes.
• OneOncologycoreStrategic or Co-development PartnerCCBD is a partner practice of OneOncology, a national network of independent community oncology practices. This partnership provides access to shared resources, best practices, and collective buying power while maintaining practice independence.
• Cancer Assistance Fund of North TexasminorOthers
• CAREITYminorOthers

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Texas Oncology: Largest community oncology practice in Texas with a similarly broad multi-specialty oncology offering (medical, radiation, surgical, hematology) and extensive geographic coverage. Most directly comparable peer given overlapping Texas footprint, service mix, and independent-practice model.
• OneOncology: National network of independent community oncology practices of which CCBD is a partner. Comparable in that the partner practices share a common service model, technology stack, and payer strategy; some practices in the network directly overlap CCBD's offerings in their respective regions.
• Hematology Oncology Associates of the Treasure Coast: Independent community hematology/oncology practice providing multi-specialty cancer care in a regional footprint. Comparable business model (physician-owned, multi-location, infusion + clinical trials) though smaller scale and different geography than CCBD.
• American Oncology Network: Network of community oncology practices offering medical oncology, hematology, infusion, and clinical research services. Comparable to CCBD as a community oncology platform with a partnership model preserving practice independence, though operating across different geographies.

Broad incumbents

• The US Oncology Network: Large national network of community oncology practices affiliated with McKesson. Offers comparable community-based medical oncology, infusion, and clinical trials services with greater geographic reach, providing a meaningful benchmark for CCBD's go-to-market and payer strategy.
• Sarah Cannon (HCA): Hospital-affiliated oncology network within HCA Healthcare, providing community-based cancer care including CAR-T and clinical trials. Comparable to CCBD in scope of advanced therapy delivery but operates through a much larger integrated health system with inpatient infrastructure.
• City of Hope: Major NCI-designated cancer center that acquired Cancer Treatment Centers of America to extend community reach. Comparable in delivering advanced cellular therapies, clinical trials, and multidisciplinary oncology, though with academic-center scale and resources CCBD does not have.
• MD Anderson Cancer Center: Premier academic cancer center based in Houston, Texas, and the dominant regional referral destination for complex oncology. Comparable as a competing provider of CAR-T and advanced therapies, though its scale, research infrastructure, and academic brand exceed what CCBD can replicate.
• Baylor Scott & White Health: Large non-profit health system with significant oncology presence across North Texas including DFW. Comparable as a competitor offering medical oncology, infusion, and radiation services within an integrated delivery network, with greater capital and inpatient resources.
• Texas Health Resources: Major North Texas health system with a growing oncology service line and direct overlap with CCBD's DFW geography. Comparable as a hospital-affiliated competitor for community oncology referrals and advanced therapy delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/TheCenterTX
• Facebookfacebook.com/thecentertx

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Center for Cancer & Blood Disorders